What:  GTx Inc. (GTXI) will visit the NASDAQ MarketSite in New York City's  Times Square.   In honor of the occasion, Dr. Mitch Steiner, Chief Executive Officer  of GTx Inc. (GTXI) will preside over the NASDAQ Opening Bell.   Where:  NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio   When:  Thursday, September 10th, 2009 at 9:15 - 9:30 a.m. ET   Contacts:  McDavid Stilwell  (901) 507-2667  mstilwell@gtxinc.com   NASDAQ MarketSite:  Robert Madden  (646) 441-5045  Robert.Madden@NASDAQOMX.com 

Feed Information:

The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on Galaxy 19 C/15, downlink frequency 4000 vertical. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.

Radio Feed:

An audio transmission of the Opening Bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About GTx Inc. (GTXI):

GTx Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to prevent and treat cancer, fractures and bone loss, muscle loss and other serious medical conditions. GTx has completed a pivotal Phase III clinical trial evaluating toremifene 80 mg to reduce the risk of fractures and to treat other estrogen deficiency side effects of androgen deprivation therapy, or ADT, in men with prostate cancer. In December 2008, GTx submitted a New Drug Application, or NDA, for toremifene 80 mg to reduce the risk of fractures in men with prostate cancer on ADT, which has been accepted for filing and review by the U.S. Food and Drug Administration, or FDA. The FDA has informed us that it has targeted October 30, 2009 as the Prescription Drug User Fee Act, or PDUFA, date by which it will respond to our toremifene 80 mg NDA. GTx is also developing toremifene 20 mg in an ongoing pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia.